The estimated Net Worth of Lukegadicke Ansbert Evnin is at least $63.7 millió dollars as of 10 February 2014. Lukegadicke Evnin owns over 466,666 units of Rigel Pharmaceuticals stock worth over $31,307,232 and over the last 21 years Lukegadicke sold RIGL stock worth over $32,395,235.
Lukegadicke has made over 16 trades of the Rigel Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Lukegadicke sold 466,666 units of RIGL stock worth $13,649,981 on 10 February 2014.
The largest trade Lukegadicke's ever made was selling 466,666 units of Rigel Pharmaceuticals stock on 10 February 2014 worth over $13,649,981. On average, Lukegadicke trades about 80,463 units every 201 days since 2004. As of 10 February 2014 Lukegadicke still owns at least 2,413,819 units of Rigel Pharmaceuticals stock.
You can see the complete history of Lukegadicke Evnin stock trades at the bottom of the page.
Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke és Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Pharmaceuticals executives and other stock owners filed with the SEC include: